
Basic Microbial Dose Response

Charles N. Haas Drexel University haas@drexel.edu



- What are the models
- How do we fit them
- Comparing models
- Confidence limits

The Risk Analysis Process



Why do we need a DR model?

- We can (never) do a direct study (even with animals) to assess dose corresponding to an acceptably low risk
- We use a model to (extrap)(interp)olate to low dose



- Average administered to a population
- Actual number an individual experiences
- Retention
- In vivo body burden after multiplication

Plausibility of Models

- should consider discrete (particulate) nature of organisms (high variability at low dose)
- based on concept of infection from one or more "survivors" of initial dose (birthdeath models)



Derivation of Exponential DR Model

- Poisson distribution of organisms among replicate doses (mean # in dose=d).
- One organism is capable of producing an infection if it arrives at an appropriate site.
- Organisms have independent and identical probability of surviving to reach and infect at an appropriate site (k).

$$p = 1 - \exp(-kd)$$
 If k=1, what does that tell us?

Derivation of Beta-Poisson Model (assumptions)

- Same as the exponential model except nonconstant survival and infection probabilities
- Survival probabilities (k) are given by the beta distribution
- Slope of dose response curve more shallow than exponential

Comparison of Exponential and Beta-Poisson (I)

Beta-Poisson Model

Original Form

$$P = 1 - \left(1 - \frac{d}{\beta}\right)^{-\alpha}$$

Revised Parameterization

$$P = 1 - \left[1 + \frac{d}{N_{50}} (2^{1/\alpha} - 1)\right]^{-\alpha}$$


0.75 exponential

1
0.75
0.5
0.02
0.25
0.0001
0.0001
0.001
0.01
0.1
1
10
100

N₅₀= organisms for 50 % infectivity



Comparison of Exponential and Beta-Poisson (II) - low dose extrapolation



A Generalized Framework




Organisms ingested -->organisms suvive to colonize -->sufficient colonies to cause effect

$$P_{I} \stackrel{\text{def}}{=} 3 \qquad 3 \qquad P_{1} \stackrel{\text{di}}{=} |\text{def}_{2} \stackrel{\text{dk}}{=} |\text{jef} \stackrel{\text{dk}}{=} |\text{min} \stackrel{\text{def}}{=} |\text{def}_{2} \stackrel{\text{dk}}{=} |\text{jef} \stackrel{\text{dk}}{=} |\text{min} \stackrel{\text{def}}{=} |\text{def}_{2} \stackrel{\text{def$$

- P(k_{min}): fraction of subjects that require k_{min} original organisms to survive in order to become infected (point; truncated Poisson, etc.)
- P₁(j|d): fraction of subjects ingesting from an average dose d who actually ingest j organisms (Poisson...)
- P₂(k|j): fraction of subjects ingesting j organisms in which k organisms survive (binomial; beta-binomial)



"Threshold (>1)" Models



- threshold models (k_{min}>1) yield steeper slopes and nonlinear low dose models
- no human data sets yet examined justify these models
 CN Haas, Drexel University



- obviously others as well
- but these do not take into account the "particle" nature of organisms
- give nonlinear lowdose behavior

Log probit

$$P_{I} = \Phi \left(\frac{1}{q_{2}} \ln \left(\frac{d}{q_{1}} \right) \right)$$

Log logistic


$$P_{I} = \frac{1}{1 + \exp[q_{1} - q_{2} \ln(d)]}$$

Weibull

$$P_I = 1 - \exp\left(-q_1 d^{q_2}\right)$$

PBDRM's

- Requires insight into biological/physical mechanisms leading to infection/disease
- May be more complex than extant data justify



Thran, personal comm.

Fitting of DR Models

Experimental Protocol

- Animals/subjects divided (randomly) into k groups
- In group "i" (i=1..k)
 - All subjects exposed to (poisson average) dose d_i
 - Of the T_i total subjects, P_i are "positive"
- Quantal
- Poisson average dose
- Binomial variability

Mechanics of Fitting (I)

each dose of our bioassay is a sample from a binomial distribution (with T_i) total organisms and an unknown positive probability (of adverse outcome) of π. so from binomial relationship, we would have:

$$f(P_i) = \frac{T_i!}{P_i!(T_i - P_i)!} \pi_i^{P_i} (1 - \pi_i)^{T_i - P_i}$$



Mechanics of Fitting (II)

but we have multiple doses (i>1, including control), and so if we use the likelihood criteria

$$\ln(L) = \sum_{i=1}^{N} \ln(f_i(P_i))$$

we would have $\ln(L) = \text{constant} + \sum_{i} \left[P_i \ln(\pi_i) + (T_i - P_i) \ln(1 - \pi_i) \right]$

 the best possible fit (maximum value of ln L) we could have is when our dose response predictor precisely goes through the observed data, i.e.,

$$\pi_i^o = rac{P_i}{T_i}$$

Any dose-response model must give a fit no better (i.e., ln L would be smaller --- more negative).



Mechanics of Fitting (III)

- it is convenient to look at the fit of some model versus the best possible, and also to multiply by -2 (to transform to minimization of a positive value, and recall χ² confidence limit behavior for likelihoods)
- obtain best fit parameters by finding (parameter vector) that minimizes Y: fit is acceptable if Y

$$\min Y = -2\sum_{i=1}^{N} \left[P_i \ln \left(\frac{\pi_i}{\pi_i^0} \right) + \left(T_i - P_i \right) \ln \left(\frac{1 - \pi_i}{1 - \pi_i^0} \right) \right]$$
 is less than the upper 5% (or 1%...) of the χ^2 distribution with


With π_i from dose-response function (function of Θ)

fit is acceptable if Y is less than the upper 5% (or 1%...) of the $\chi 2$ distribution with degrees of freedom = number of doses minus number of dose response parameters

Data Fitting Methodology

- Y provides an index of goodness of fit
 - test vs chi square doses-(# params)
- Unconstrained nonlinear optimization
 - Excel
 - R
 - (Matlab, Mathematica ...)

Example of Point Estimation



- rotavirus (human)
- BP fits better than others, and is accepted as adequate


CN Haas, Drexel University



Characterizing Uncertainty-Confidence Limits

- Confidence regions determined from Likelihood Ratio approach
- all Θ in confidence region if $2\left[L(\Theta)-L(\hat{\Theta})\right]<\chi^2$
- need to determine n-dimensional region, which may or may not be closed
- can be done in Excel (but tedious and slow)

Example Uncertainty: Rotavirus






outlier

$$r_{i} = sign\left(p_{i}^{0} - \tilde{p}_{i}\right) \bullet 2 \left[P_{i} \ln\left(\frac{\tilde{p}_{i}}{p_{i}^{0}}\right) + \left(T_{i} - P_{i}\right) \ln\left(\frac{1 - \tilde{p}_{i}}{1 - p_{i}^{0}}\right)\right]$$

overdispersion

systematic deviations



Dealing with Outliers

- identification by likelihood (fit by removal of outliers and compute likelihood ratio)
 - signficance levels confirmed by Monte Carlo
- problems with multiple outliers (masking, swamping)
- not yet a well treated problem in statistics (nonnormal, non-linear models)
- outlier identification is typically with respect to a model -- hence we must place "trust" in a model to identify outliers



- Replace a binomial likelihood with a beta-binomial
- This introduces an extra parameter
- Most dose-response studies do not have sufficient dose levels or replicates to truly validate this approach

Dealing with Systematic LOF

- systematic trends in deviance residuals are suggestive of need to use a different dose-response model
- perhaps one with additional parameters